Almac Expands UK Commercial Capacity
News Oct 05, 2012
Almac has announced that it has expanded its MHRA/FDA approved UK commercial packaging facility with the acquisition of a Noack N 623 blister packaging line from Romaco.
The acquisition comes in response to growing client demand for enhanced flexibility related to larger blister sizes and innovative multi unit blister formats, coupled to a requirement for non permeability and enhanced environmental protection, particularly product humidity control.
This highly flexible, cGMP compliant technology can be configured to process both thermoform and coldform materials, with maximum blister sizes of 220mm x 155mm.
With its automatic feeding system, filling inspection and ejection station and shorter set-up times, the line provides increased productivity, processing over 25,000 blisters per hour, including multi-product blisters.
“Blister size and dosage formats are becoming increasingly more complex. Additionally, product handling for innovative new molecules often requires enhanced environmental controls. This investment allows Almac, through its Pharma Services business unit, to offer this additional flexibility,” says Geoff Sloan VP of Manufacturing Operations.
“Through this acquisition, coupled with our immanent entry into the US commercial packaging market, we continue to expand our capabilities and flexibility to meet our client’s needs.”
“The blister technology from Romaco Noack offers high OEE values and low lifecycle costs. Product changeovers are carried out easily and cleaning is quickly done. Our machines prove themselves flexible in operation and versatile in use.”, says Bernd Webel, Sales Director, Romaco.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development PartnershipNews
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.READ MORE